FDA approves long-term use of semaglutide-based Wegovy weight loss drug for eligible individuals.
Wegovy, a weight loss drug containing semaglutide, has been approved by the FDA for long-term use in individuals with a BMI of 30 or higher, or 27 or greater with other conditions. The medication mimics the GLP-1 hormone, leading to appetite suppression, reduced calorie intake, and increased satiety, resulting in significant weight loss. Potential side effects include nausea, diarrhea, constipation, and vomiting, with rarer side effects including pancreatitis, gallbladder disease, and kidney problems. Wegovy differs from its sister medication, Ozempic, which is used for treating type 2 diabetes. Both drugs are not subsidized through Australia's Pharmaceutical Benefits Scheme, leading to a high price tag for users.
August 27, 2024
126 Articles